what not to take with semaglutide Who Should GLP-1 Drugs? How to Not Gain Weight

Second, oral semaglutide tablet and sublingual drop users post far more polarized reviews some report results, many report none and switch to injectables

While both target metabolic disease, tirzepatide is a GIP/GLP1 dual agonist injectable, whereas orforglipron is a selective, oral GLP1 receptor agonist

There are specific circumstances in which you should seek prompt medical advice, either from your trial team or your GP: Persistent insomnia lasting more than three to four weeks that is significantly affecting your daytime functioning, mood, or concentration Symptoms of anxiety or low mood that have developed or worsened since starting treatment, as these can both cause and be exacerbated by poor sleep Signs of obstructive sleep apnoea such as loud snoring, gasping during sleep (reported by a partner), or excessive daytime sleepiness which require formal assessment and may need referral to a sleep clinic New or worsening palpitations or an irregular heartbeat at night GLP-1-based medicines can be associated with a modest increase in resting heart rate

The NIHs Office of Dietary Supplements says most peoples results fall somewhere between about 200 and 800 picograms per milliliter